Komori
N

Nippon Shinyaku Co.,Ltd.

4516PharmaceuticalsMid cap
3,466JPY+0.7%
★ Watch (sign-up required)
Price history
¥3,466Latest-58.7%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

A group whose principal business is the manufacture and sale of pharmaceuticals and functional foods. Its two core business segments are pharmaceuticals and functional foods. Its overseas operations comprise NS Pharma, Inc., 北京艾努愛世医薬科技有限公司 and 天津艾努愛世医薬有限公司. In Japan, it manufactures and sells pharmaceuticals and functional foods while receiving manufacturing and supplies through シオエ製薬株式会社 and タジマ食品工業株式会社. In the functional foods business, タジマ食品工業株式会社 supplies the raw materials, and some processing is outsourced to that company. 日本新薬アドバンス株式会社 provides business support services.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
24.09How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.82How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
3.4%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥243bnShare price × number of shares. The value of the entire company.
Equity ratio
85.6%The proportion of assets funded by money that does not have to be repaid.
Operating margin
25.1%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
9.8%The average annual growth in sales over the past three years.
What to watch next
The PDUFA date for CAP-1002 (deramiocel), set for 22 August 2026 following the resumption of the FDA review, and the review outcome
August 2026 (PDUFA date)Impact HighLikelihood Medium
Initiation of a Phase 3 trial for NS-304 (selexipag) from April 2026
April 2026Impact MediumLikelihood Medium
Progress in addressing the FDA clinical hold received for RGX-111 (gene therapy) in January 2026, including the status of its lifting and trial resumption
2026 (specific timing unclear)Impact MediumLikelihood Low
Stabilization of the production system through the completion and ramp-up of major capital investments, including the nucleic acid API purification facility at the Odawara Comprehensive Pharmaceutical Plant (scheduled for completion in the first quarter of fiscal 2025)
After completion in fiscal 2025 through the ramp-up reflected in 2026Impact MediumLikelihood Medium
The specific implementation of drug price revisions and healthcare cost containment in Japan, including their impact on sales and gross profit
Throughout the fiscal year, depending on the revision cycleImpact HighLikelihood High
What to watch next
Loading
Who owns itTop holders total 46.6%
Listed holders 46.6%Everyone else 53.4%
The Master Trust Bank of Japan, Ltd. (Trust Account)12.02%
明治安田生命保険相互会社9.62%
株式会社日本カストディ銀行 (Trust Account)7.30%
The Bank of Kyoto, Ltd.4.58%
株式会社三菱UFJ銀行4.02%
日本生命保険相互会社1.99%
STATE STREET BANK AND TRUST COMPANY1.91%
THE BANK OF NEW YORK MELLON1.74%
2 other listed holders3.39%
Who owns it
HolderOwnership (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)12.02
明治安田生命保険相互会社9.62
株式会社日本カストディ銀行 (Trust Account)7.30
The Bank of Kyoto, Ltd.4.58
株式会社三菱UFJ銀行4.02
日本生命保険相互会社1.99
STATE STREET BANK AND TRUST COMPANY1.91
THE BANK OF NEW YORK MELLON1.74
2 other listed holders3.39
This company's documents
Filings
Timely disclosures